Entrada Therapeutics, Inc.
NASDAQ:TRDA
12.25 (USD) • At close January 15, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 19.57 | 94.694 | 59.12 | 41.848 | 43.735 | 18.17 | 25.26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.9 | 0.9 | 0.934 | 0.736 | 0.8 | 0.7 | 0.541 | 0.525 | 0.5 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 18.67 | 93.794 | 58.186 | 41.112 | 42.935 | 17.47 | 24.719 | -0.525 | -0.5 | -0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0.954 | 0.99 | 0.984 | 0.982 | 0.982 | 0.961 | 0.979 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 31.257 | 31.135 | 27.674 | 27.555 | 22.191 | 26.3 | 23.102 | 15.685 | 18.958 | 16.248 | 15.718 | 12.362 | 10.513 | 6.829 | 6.223 | 6.656 | 5.7 | 4.373 | 4.373 |
| General & Administrative Expenses
| 9.971 | 9.236 | 9.399 | 8.652 | 7.532 | 8.169 | 7.938 | 9.894 | 6.978 | 7.334 | 6.433 | 6.098 | 3.851 | 3.081 | 2.17 | 1.997 | 1.273 | 1.148 | 1.148 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 9.971 | 9.236 | 9.399 | 8.652 | 7.532 | 8.169 | 7.938 | 9.894 | 6.978 | 7.334 | 6.433 | 6.098 | 3.851 | 3.081 | 2.17 | 1.997 | 1.273 | 1.148 | 1.148 |
| Other Expenses
| 0 | -32.035 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 41.228 | 40.371 | 37.073 | 36.207 | 29.723 | 34.469 | 31.04 | 25.579 | 25.936 | 23.582 | 22.151 | 18.46 | 14.364 | 9.91 | 8.393 | 8.653 | 6.973 | 5.521 | 5.521 |
| Operating Income
| -21.658 | 53.423 | 21.113 | 4.905 | 14.012 | -16.299 | 1.322 | -25.579 | -25.936 | -23.582 | -22.151 | -18.46 | -14.364 | -9.91 | -8.393 | -8.653 | -6.973 | -5.521 | -5.521 |
| Operating Income Ratio
| -1.107 | 0.564 | 0.357 | 0.117 | 0.32 | -0.897 | 0.052 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 5.766 | 4.366 | 4.214 | 4.292 | 4.051 | 4.218 | 2.657 | 0.95 | 0.799 | 0.403 | 0.48 | 0.013 | -0.066 | 0.009 | 0.013 | -0.02 | -0.017 | 0.091 | 0.091 |
| Income Before Tax
| -15.892 | 57.789 | 25.327 | 9.197 | 18.063 | -12.081 | -3.123 | -24.629 | -25.137 | -23.179 | -21.671 | -18.447 | -14.43 | -9.901 | -8.38 | -8.673 | -6.99 | -5.43 | -5.43 |
| Income Before Tax Ratio
| -0.812 | 0.61 | 0.428 | 0.22 | 0.413 | -0.665 | -0.124 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -1.86 | 2.758 | 1.831 | 18.741 | -17.398 | 13.847 | 3.551 | -2.425 | -1.598 | -0.806 | -0.96 | -0.013 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income
| -14.032 | 55.031 | 23.496 | -9.544 | 35.461 | -25.928 | -6.674 | -22.204 | -23.539 | -22.373 | -20.711 | -18.434 | -14.43 | -9.901 | -8.38 | -8.673 | -6.99 | -5.43 | -5.43 |
| Net Income Ratio
| -0.717 | 0.581 | 0.397 | -0.228 | 0.811 | -1.427 | -0.264 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.35 | 1.61 | 0.7 | -0.29 | 1.07 | -0.78 | -0.21 | -0.71 | -0.75 | -0.72 | -0.66 | -0.89 | -0.51 | -0.48 | -0.41 | -0.42 | -0.34 | -5.18 | -5.18 |
| EPS Diluted
| -0.35 | 1.55 | 0.68 | -0.29 | 1.02 | -0.78 | -0.21 | -0.71 | -0.75 | -0.72 | -0.66 | -0.89 | -0.51 | -0.48 | -0.41 | -0.42 | -0.34 | -5.18 | -5.18 |
| EBITDA
| -21.658 | 53.423 | 22.047 | 5.641 | 14.012 | -15.569 | -5.239 | -25.053 | -25.42 | -23.119 | -21.761 | -18.096 | -14.062 | -9.658 | -8.194 | -8.555 | -6.883 | -5.452 | -5.452 |
| EBITDA Ratio
| -1.107 | 0.574 | 0.373 | 0.135 | 0.32 | -0.897 | -0.229 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |